“associations between changes in physical function and PA or SB with some of the selected biomarkers, namely TNF-alpha, troponins and most convincingly in cystatin C”
Caloric restriction decreases cystatin C in humans (older adults with obesity; compared with weight stability) (WL: -2.53 ng/mL versus WS: 0.07 ng/mL; p = .04).
Alcohol dependence treatment program is linked with lower cystatin C in humans (measured before and after the treatment program in patients with alcohol dependence).
“beta-2-microglobulin and Cystatin C decreased after the treatment program than before”
Humansmeasured before and after the treatment program in patients with alcohol dependence
Cystatin C is linked with kidney failure in humans (Mediation of the relationship between body mass index and renal failure) (12.34% mediated).
“five acted as mediators in the relationship between BMI and renal failure: cystatin C (12.34%), glucose (7.02%), glycated hemoglobin (HbA1c) (6.83%), diastolic blood pressure (6.37%)”
HumansMediation of the relationship between body mass index and renal failure
Cystatin C is linked with bone mineral density in humans (DBP-dependent).
“renal biomarker cystatin C and endocrine biomarker IGF-1 exhibited DBP-dependent associations with BMD, mediating the nonlinear DBP-bone density relationship”
Cystatin C improves GFR estimation accuracy (CKD diagnosis and staging).
“Cystatin C-inclusive equations generally outperform creatinine-based equations in bias and accuracy across diverse populations, including children and patients with comorbidities.”
Cystatin C was not clearly linked with major adverse kidney events in humans (independent of eGFR, albuminuria and CKD risk factors) (OR 0.94 (95% CI 0.74-1.19)).
“No significant association was observed for urine CysC (OR: 0.94, 95% CI: 0.74-1.19).”
Humansindependent of eGFR, albuminuria and CKD risk factorsurine13 years of follow-up
Cystatin C is linked with atherosclerosis in humans (8.22% mediated).
“Mediation analysis revealed that cystatin C partially mediated (8.22%) the effect of ANGPTL8 on atherosclerosis, whereas triglycerides showed negligible mediation.”
HumansPartial mediation of the ANGPTL8–atherosclerosis association in patients with type 2 diabetesn = 202
Cystatin C predicts mortality in patients with angiographically verified coronary artery disease (standardized adjusted HR 1.20 [1.13-1.28], p<0.001).
“Cystatin C proved to be a strong and independent predictor for mortality in the total study cohort (standardized adjusted HR 1.20 [1.13-1.28], p<0.001).”
Cystatin C predicts mortality in humans (C-index from 0.745 to 0.839, AUC from 0.751 to 0.845).
“The predictive performance significantly improves by including longitudinal changes in Cystatin C in baseline-only models, with the concordance index increasing from 0.745 to 0.839 and the area under the receiver operator characteristic curve rising from 0.751 to 0.845.”
Cystatin C is linked with a higher risk of mortality in humans (HR: 1.51, 95 % CI: 1.02-2.24, p = 0.04).
“Participants in the highest quartile of baseline Cystatin C show an increased risk of mortality compared to those in the lowest quartile (hazard ratio (HR): 1.51, 95 % CI: 1.02-2.24, p = 0.04).”
Cystatin C is linked with a higher risk of mortality in humans (participants in the fourth quartile (≥ 0.877 mg/L) vs. first quartile (< 0.659 mg/L)) (HR: 2.71, 95% CI: 2.17-3.38).
“HR: 2.71, 95% CI: 2.17-3.38, P < 0.001; respectively”
Humansparticipants in the fourth quartile (≥ 0.877 mg/L) vs. first quartile (< 0.659 mg/L)15.62 ± 4.68 yearsn = 9,894
Cystatin C is associated with mortality in humans (hip fracture) (HR 2.19, 95 % CI: 1.72-2.79, P < 0.0001).
“Linear multivariate Cox regression analysis revealed a significant association between preoperative cystatin C level and death, with a hazard ratio (HR) of 2.19 (95 % confidence interval [CI]: 1.72-2.79, P < 0.0001).”
Cystatin C is associated with frailty in humans (β = 0.050 SD/y, 95% CI, 0.045-0.055 SD/y).
“Each SD increment in serum cystatin C was associated with a faster increase in FI in both the HRS cohort (β = 0.050 SD/y; 95% CI, 0.045-0.055 SD/y; P = .001)”
Cystatin C is associated with frailty in humans (OR 3.13, 95% CI 2.03–4.82, quartile 4 versus 1; frail versus robust).
“a threefold greater odds of frailty versus robust (OR quartile 4 vs 1; 3.13, 95% CI 2.03-4.82)”
HumansWithout overt frailty at baseline; highest versus lowest cystatin C quartile; adjusted for age, clinical site, and raceAverage of 3.4 yearsmalesn = 2,613
Cystatin C is linked with a higher risk of stroke in both males and females.
“High DBP, systolic blood pressure, total metabolic output, and Cystatin C in both males and females were still significantly associated with the risk of stroke (P < .05).”
Cystatin C is linked with a higher risk of stroke in humans after adjusting for confounding factors, highest vs lowest quartile (OR 1.380, 95% CI 1.046-1.825).
“those in the last quartile had the greatest risk of stroke incidence [odds ratio (OR), 1.380; 95% confidence interval (CI), 1.046-1.825]”
Humansafter adjusting for confounding factors, highest vs lowest quartile
Cystatin C predicts stroke in humans (obstructive sleep apnea) (AUC 0.731, 95% CI 0.683-0.779).
“capability of Cys-C to identify elderly patients with OSA who had a long-time risk of stroke was moderate (AUC = 0.731, 95% CI: 0.683-0.779, P = 0.001).”
Cystatin C is linked with a higher risk of stroke in humans (obstructive sleep apnea) (HR 2.16, 95% CI 1.09-6.60).
“patients with a serum Cys-C concentration of ≥1.15 mg/L had a 2.16-fold higher risk of developing stroke compared with patients with serum Cys-C ≤ 0.81 mg/L”
Humansobstructive sleep apneaserum≥1.15 mg/L vs ≤0.81 mg/Lmedian 42-monthn = 932
Cystatin C is linked with a higher risk of cardiovascular mortality in humans (participants in the fourth quartile (≥ 0.877 mg/L) vs. first quartile (< 0.659 mg/L)) (HR: 3.36, 95% CI: 2.06-5.46).
“the risk of cardiovascular and all-cause death increased 2.36-fold and 1.71-fold for participants in the fourth quartile (≥ 0.877 mg/L) (HR: 3.36, 95% CI: 2.06-5.46, P < 0.001”
Humansparticipants in the fourth quartile (≥ 0.877 mg/L) vs. first quartile (< 0.659 mg/L)15.62 ± 4.68 yearsn = 9,894
Cystatin C predicts cardiovascular mortality in humans (Age-adjusted analysis; per 0.1-unit increase) (HR 1.18 (95% CI 1.09–1.28) per 0.1-unit increase).
“cystatin C predicted the risk of non-cardiovascular and cardiovascular death in men”
HumansAge-adjusted analysis; per 0.1-unit increase9 yearsmales
Cystatin C is associated with telomere length in humans (adjusted for immune cell type distributions) (-0.0391 kilobase pairs per unit; 95% CI -0.0772 to -0.00107).
“cystatin C -0.0391 (95% CI -0.0772--0.00107)”
Humansadjusted for immune cell type distributionsleukocyten = 7,252
Cystatin C is associated with major adverse cardiovascular events in humans (Placebo-treated patients with type 2 diabetes; fourth versus first quartile).
“higher baseline CysC was associated with higher risk for CVD/HHF, MACE, and the kidney-specific composite outcome.”
HumansPlacebo-treated patients with type 2 diabetes; fourth versus first quartilen = 1,899
American heart journal plus : cardiology research and practice·
Cardiovascular disease
↕mixedin humans1↑upin humans1
2 studies
Cardiovascular disease is associated with cystatin C in humans (cross-lagged path analysis).
“The bidirectional CVD-TyG-BMI relationship and unidirectional CVD-cystatin C association suggest comorbidity risks between cardiovascular, metabolic, and renal diseases.”
Cystatin C is linked with a higher risk of cognitive impairment in humans (fully adjusted) (OR 1.49, 95% CI 1.24-1.79).
“Each 1-SD increase in CysC levels was significantly associated with 49% higher odds of cognitive impairment after full adjustment [odds ratio (OR) = 1.49, 95% confidence interval (CI): 1.24-1.79, p < 0.001].”
Cystatin C is associated with contrast-associated acute kidney injury detection in humans (7 cystatin C-defined cases versus 4 creatinine-defined events; no overlapping cases; κ = 0.07).
“Creatinine-based criteria identified 4 CA-AKI events, whereas cystatin C identified 7 additional early functional injury cases.”
Human trialPatients with peripheral arterial disease undergoing elective intra-arterial contrast-enhanced vascular procedures; comparison with creatinine-based criterian = 76
Cystatin C predicts waist circumference in humans (β = 0.500).
“In addition, Δcystatin C (β = 0.500) was considered an independent explanatory variable for the change in waist circumference (Δwaist circumference).”
Cystatin C is associated with physical function and physical activity changes in humans (changes over a 16-week physical activity intervention).
“associations between changes in physical function and PA or SB with some of the selected biomarkers, namely TNF-alpha, troponins and most convincingly in cystatin C”
Human trialchanges over a 16-week physical activity intervention16 weeksn = 339
Low versus preserved kidney function on a second test was linked to higher death risk, with hazard ratios of 1.44 and 1.62.Low versus preserved kidney function on a second test was linked to higher death risk, with hazard ratios of 1.44 and 1.62.